A patent for a new kind of medical device may be on the horizon.
The FDA recently granted the American company a patent for an implantable “genetic therapy” to treat a condition that is rare in the U.S. The device uses a gene that is found in human cells to create a protein that then binds to a protein in the body.
The implantable device is currently in development by the pharmaceutical company Thermo Fisher Scientific, and the FDA has granted preliminary approval for it to be marketed under the trade name, Genetically Engineered Organon.
The company has been working on the gene-editing technology for years, and has applied for at least three patents for its product.
The first two applications are pending, but one was denied.
Thermo says that it is now seeking to obtain a patent extension.
The Gene-edited Organon is a small device, measuring about the size of a water bottle, that could be inserted into a patient’s vein and injected into a vein or artery.
The gene-edited version of the organon works like a gene in human DNA that was deleted.
The new gene-modified version can be made in vitro to bind to a specific protein in human blood.
In addition to its new product, Thermo is working on a small version of its gene-injector that can be inserted in a vein in a patient.
Thermoes goal is to eventually offer the product in pill form, but the company has not announced any plans for a product yet.